Israel-based pharmaceutical major Teva Pharmaceutical has reached a settlement with Takeda Pharmaceutical.
Teva has entered into an agreement with Takeda over claims that the company breached patents relating to Teva's generic versions of Takeda's Type 2 diabetes drugs ACTOS and ACTOplus in the US.
Takeda has now granted Teva a licence to market a generic version of ACTOS in the US as of 17 August 2012, and ACTOplus beginning on 14 December 2012. Both licences could be invoked earlier under certain circumstances.
The branded products achieved combined sales of $4bn in the US.
SOURCE: Pharmaceutical-technology 